COMPASS Pathways launches new podcast "Everyone has a story: talking about mental health"


London, UK 30 June 2021


COMPASS Pathways plc (Nasdaq: CMPS) ("COMPASS"), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, launched a new podcast today – "Everyone has a story: talking about mental health".

The podcast will feature influential guests who will talk about their mental health journeys, share their personal stories, and discuss critical issues in mental health care, including compassion and patient access. Everyone has a story: talking about mental health aims to open up dialogue about mental health challenges, to reduce stigma and to secure better care for those who are suffering.

The first episode will feature mental health campaigner and former UK government health minister, Sir Norman Lamb, who is currently Chair of South London and Maudsley NHS Foundation Trust and Chairman of the Children's and Young People's Mental Health Coalition in the UK. He joins COMPASS Pathways CEO and Co-founder George Goldsmith to talk about the experiences of dealing with mental health difficulties in their own families, the impact of COVID-19, and the challenges facing mental health care systems today.

Sir Norman Lamb said: "It's really important to open up about mental health. Our family has been touched by mental ill health just like most families. Talking about our experiences makes it a little easier for others to seek help when they are worried about what's going on in their head. I hope the podcast will contribute to this public discussion. We have made real progress over the last 10 years in reducing stigma relating to mental ill health but we still have a long way to go to complete the revolution!"

Episode two, to be released in July, will feature Grammy-award nominated singer, New York Times bestselling author and mental health advocate, Jewel, who will be talking about how she overcame her mental health challenges as a teenager, how she maintains her mental wellbeing today, and her Inspiring Children's Foundation.

Jewel said: "As kids, we're not taught mental hygiene and emotional hygiene in the same way that we're taught, say, dental hygiene. And yet our teeth are nowhere near as important as learning how to curate our thoughts. We need to teach a new emotional language, one that will help children and young people to take charge of their own happiness. That starts by having the conversations and talking openly about mental health, as we're doing through this podcast."

George Goldsmith said: "We are living through a growing mental health care crisis. Even before COVID, one in four people experienced some form of mental health challenge, with more than 320 million people around the world suffering with depression. One person dies from suicide every 40 seconds, and in that time 20 more people attempt it. Mental health care remains woefully inadequate for the vast majority of sufferers and stigma is still a huge issue.

"Our vision at COMPASS is a world of mental wellbeing, a world in which there is no stigma around mental health, and people have choices in how they manage their mental health care. We hope the stories that unfold on " Everyone has a story " will inspire listeners to share their own experiences, and open up conversations everywhere about mental health and mental health care."

Subscribe to "Everyone has a story: talking about mental health" on the COMPASS website or by searching for it on your favourite podcast app.

-Ends-


About COMPASS Pathways

COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression (TRD), and we are currently conducting a phase IIb clinical trial of psilocybin therapy for TRD, in 22 sites across Europe and North America. We are headquartered in London, UK, with offices in New York, US. Our vision is a world of mental wellbeing. www.compasspathways.com

Availability of other information about COMPASS Pathways

Investors and others should note that the Company communicates with its investors and the public using its website (www.compasspathways.com), its investor relations website (ir.compasspathways.com), and on social media (LinkedIn), including but not limited to investor presentations and investor fact sheets, US Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information posted on these channels and websites could be deemed to be material information. As a result, we encourage investors, the media, and others interested in the Company to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on our investor relations website and may include additional social media channels. The contents of the Company's website or these channels, or any other website that may be accessed from the website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

Forward-looking statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. In some cases, forward-looking statements can be identified by terminology such as "may", "might", "will", "could", "would", "should", "expect", "intend", "plan", "objective", "anticipate", "believe", "contemplate", "estimate", "predict", "potential", "continue" and "ongoing," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements include express or implied statements relating to, among other things, the safety profile of COMP360 and the efficacy of COMP360 psilocybin therapy as a treatment for depression, COMPASS's business strategy and goals, COMPASS's ability to continue to advance its research, including COMP360, and COMPASS's expectations regarding the benefits of its COMP360 psilocybin therapy. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond COMPASS's control and which could cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by these forward-looking statements.

These risks, uncertainties, and other factors include, among others: preclinical research and clinical development is lengthy and uncertain, and therefore our preclinical studies and clinical trials may be delayed or terminated, or may never advance to or in the clinic; and those risks and uncertainties described under the heading "Risk Factors" in COMPASS's annual report on Form 20-F filed with the US Securities and Exchange Commission (SEC) on 9 March 2021 and in subsequent filings made by COMPASS with the SEC, which are available on the SEC's website at www.sec.gov. Except as required by law, COMPASS disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on COMPASS's current expectations and speak only as of the date hereof.

Enquiries

Media: Tracy Cheung, tracy@compasspathways.com, +44 7966 309024
Investors: Stephen Schultz, stephen.schultz@compasspathways.com, +1 401 290 7423

Attachments


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

The Conversation (0)

Seelos Therapeutics Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis Study with SLS-005

Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today provided an update on top-line data of the Phase 23 HEALEY ALS Platform trial. This study was performed in collaboration with The Sean M. Healey and AMG Center, which is viewed as an influential force in ALS research and in caring for the ALS community. Their unique and innovative approach continues to be a benefit to the ALS community and its contributions have helped bring the last two FDA approved therapies for ALS to market.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Melodiol Global Health Limited

Appendix 4E Preliminary Final Report Year Ended 31 December 2023

Melodiol Global Health Limited (ASX:ME1) (‘Melodiol’ or ‘the Company’) is pleased to present its Preliminary Final Year Report.

Keep reading...Show less

Compass Pathways Announces Fourth Quarter 2023 Financial Results and Business Highlights 

-

Highlights:
  • COMP360 phase 3 pivotal program ongoing; COMP005 trial top-line data now expected in fourth quarter 2024, COMP006 remains on track for top-line data in mid-2025
  • Teri Loxam to assume Chief Financial Officer role on March 1, 2024
  • Cash position of $220.2 million at December 31, 2023, additional $31.4 million net cash raised to date in first quarter 2024
  • Conference call February 29 at 8:00 am ET (1:00 pm UK)


Compass Pathways plc (Nasdaq: CMPS) ("Compass"), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the fourth quarter 2023 and provided an update on recent progress across its business.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Compass Pathways to participate in upcoming TD Cowen investor conference

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in a panel discussion at the TD Cowen 44th Annual Health Care Conference at 12:50 pm ET on March 4, 2024.

A live audio webcast of the panel discussion will be accessible from the "Events" page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following such event. For more information, please visit investor section of compasspathways.com.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Compass Pathways to announce fourth quarter and year-end 2023 financial results on February 29, 2024

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the fourth quarter and year-end 2023 ending December 31, 2023, and provide an update on recent business developments, on February 29, 2024.

The management team will host a conference call at 8:00 am ET (1:00 pm UK) on February 29, 2024. To access the call, please register in advance here to obtain a local or toll-free phone number and your personal pin.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Melodiol Global Health Limited

Capital Raising & Corporate Update

Melodiol Global Health Limited (ASX:ME1) (‘Melodiol’ or ‘the Company’) is pleased to advise it has received firm commitments to raise ~$1.08m (before costs) through the issue of approximately 106,415,113 new fully paid ordinary shares (‘Shares’) at an issue price of $0.01019 per Share (the ‘Placement’).

Keep reading...Show less

Latest Press Releases

Related News

×